# A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

> **NCT00190697** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 70 (—)

## Conditions studied

- Breast Cancer
- Endometrial Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** arzoxifene

## Key facts

- **NCT ID:** NCT00190697
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** —
- **Final completion:** 2007-04
- **Target enrollment:** 70 (—)
- **Last updated:** 2007-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00190697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00190697, "A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT00190697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*